Interferon beta-1b

干扰素β-1b

Report date: 2022/08/16 20:00:19

Base Information

Drug NameInterferon beta-1b
Drug Alias NameInterferon β-1b倍他干扰素-1bInterferon beta-Serinterferon beta-1b(Bayer)Extavia +[16] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)CardiomyopathiesHeart Diseases +[5] 
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaMultiple Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date1993/07/23
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma AgBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesBayer AGBayer Healthcare Pharmaceuticals
Inactive CompaniesUniversity Of TurinThe University Of Hong KongNuron Biotech Inc
Active IndicationsMultiple Sclerosis
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)CardiomyopathiesHeart Diseases +[4] 

Other Information

ATC CodeL03AB08
Related LinksWikipediaDrugBankKEGG